2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.17 Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis

EP.11A.17 Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis

Back to course

Pdf Summary

The study investigated the effectiveness of combining tislelizumab, chemotherapy, and bone-targeted agents in the first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with bone metastasis. It included 29 untreated NSCLC patients who underwent 4-6 cycles of tislelizumab plus chemotherapy and bone-targeted treatment, with subsequent maintenance therapy using tislelizumab and these agents until disease progression.<br /><br />The primary measure of success was Progression-Free Survival (PFS), with secondary endpoints including Object Response Rate (ORR), Disease Control Rate (DCR), Overall Survival, and safety outcomes. The findings displayed an ORR of 65.5% and a DCR of 86.2%. The median PFS for the cohort was nine months. It was noted that pre-treatment values of the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) could predict treatment outcomes. Specifically, higher NLR and PLR were linked to longer PFS, with the NLR threshold of 5 showing more significant results (11.0 months vs. 6.0 months, p = 0.006).<br /><br />The safety assessment indicated that mild adverse events (grades 1-2) occurred in 15 patients, including rash and hypothyroidism, while two patients experienced grade 3 events such as liver dysfunction and enteritis. No severe adverse effects (grades 4 or 5) were observed.<br /><br />In conclusion, the combination of tislelizumab, chemotherapy, and bone-targeted agents demonstrated promising results for treating advanced NSCLC with bone metastasis, highlighting the importance of baseline NLR and PLR as potential indicators for treatment efficacy. This study offers insights into tailoring treatment plans based on these predictive biomarkers.

Asset Subtitle

Yina Wang

Meta Tag

Speaker Yina Wang

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

tislelizumab

chemotherapy

bone-targeted agents

non-small cell lung cancer

bone metastasis

Progression-Free Survival

neutrophil-lymphocyte ratio

platelet-lymphocyte ratio

treatment outcomes

predictive biomarkers